Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label multiple-dose intramuscular HZBio1 study in gout with inadequately controlled serum uric acid after oral urate-lowering therapy
CTR20242092Phase 2Completed
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Jun 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HZBio1 in gout, hyperuricemia, sponsored by Chongqing Paijin Biotechnology. Started Jun 2024; status: completed.
02
Drugs
HZBio1
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20242092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242092.